Phathom pharmaceuticals, inc.PHAT.US Overview

US StockHealthcare

(No presentation for PHAT)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

PHAT Overall Performance

PHAT AI Analysis & Strategy

PHAT Recent Performance

1.03%

Phathom pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

PHAT PowerScanner

PHAT Key Information

PHAT Valuation Metrics

PHAT Earnings Table

PHAT Profile

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.